UBS Downgrades Merck (MRK) to Neutral
More News related to MRK
- National BDPA and WorkplaceDiversity.com Announce Winners of the 2009 Best Companies for Blacks in Technology Award
- Merck Prices $4.25 Billion Debt Offering
- Notable Mergers and Acquisitions of the Day 6/22: TWGP/SUAI, MRK/SGP, AAUK
- Vical (VICL) Receives $1.5M Milestone Payment from Merck (MRK)
- Merck (MRK) and Schering-Plough (SGP) Receives FTC "Second Request" for Additional Information On Merger
UBS downgrades Merck (NYSE: MRK) from Buy to Neutral and cuts its price target from $43 to $40.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
-1.77Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
